Skip to main content
SpringerLink
Log in

DuoResp Spiromax cost saving for COPD in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Darba J, et al. Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain. ClinicoEconomics and Outcomes Research 2017: 127-137, No. 9, 10 Feb 2017. Available from: URL: https://doi.org/10.2147/CEOR.S125301

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DuoResp Spiromax cost saving for COPD in Spain. PharmacoEcon Outcomes News 772, 16 (2017). https://doi.org/10.1007/s40274-017-3764-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3764-7

Search

Navigation